 CAMBRIDGE, Mass.--BUSINESS WIRE--Infinity Pharmaceuticals, Inc. NASDAQ: INFI, a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, March 29th, 2022 at 4:30 p.m. ET to report its financial results for the fourth quarter and full year 2021. Conference call Webcast Details Date: Tuesday, March 29th Time: 4:30 pm Eastern Time Webcast: 